News

Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...

A mix of high expectations, profit-taking, and a slight dip in valuations has sent S&P 500 stocks sputtering even after solid earnings reports.

Investors pay particular attention to a health insurer’s second-quarter report, which reflects more medical claims data among members.

CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.

Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336.

Cigna Group (NYSE:CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that management said exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71

Adjusted EPS of $7.78 beats expectations, leading to a full-year outlook increase to at least $30.45, as Specialty and Care Services surge 22%.

Cigna delivers an earnings and revenue beat as Cigna Healthcare fuels growth, while the company raises its 2026 EPS outlook despite higher pharmacy costs.

The headline numbers for Cigna (CI) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cigna (CI) delivered earnings and revenue surprises of +2.64% and +0.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- The Cigna Group (NYSE:CI) reported second-quarter earnings and revenue that exceeded analyst expectations, while raising its full-year outlook, though shares fell 1% premarket following the announcement.

Cigna Group lifted its outlook and reported a higher profit in the second quarter, driven by growth in both its healthcare and pharmacy-benefit businesses.

Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.

Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.

UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs and gave a big boost to its full-year outlook. Humana, Centene and CVS Health all got a sizable lift from the warm reception for UnitedHealth's earnings report.

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se

(Update with the Justice Department's response to a request for comment in the third paragraph.)

Cigna is scheduled to post its second-quarter results later this month, and analysts project a single-digit earnings growth.

Before the stock surged, management laid out a turnaround plan for its Aetna unit that was so explicit, they practically put a price tag on it.

Cigna Group stock has delivered a 34.3% gain over the past 5 years, yet the shares have fallen 8.0% over the last year and still screen as cheap on the latest valuation checks. That mix of solid long term returns, recent share price weakness, and a high value score sets up a clear question about whether the current price around US$287.77 fairly reflects the business today. Over 5 years, Cigna Group has returned 34.3%, which points to a business that has rewarded patient shareholders even...

Cigna trades at $298.08 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 8.4%.

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan

Pre-Market Stock Futures: Futures are trading higher on the heels of the third straight day of stock declines, and there is growing apprehension that yields will go even higher and that inflation may as well. All of the major indices finished Tuesday lower, and with Q1 earnings all but over and the incoming economic data ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: BJ’s Wholesale Club, Centene, Cigna, Crown Castle, ETSY, Franco-Nevada, Humana, Ovintiv, X-Energy, and More

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.87%. June E-mini S&P futures (ESM26 ) fell -0.16%, and June E-mini Nasdaq futures...

CVS Health’s Aetna was the third-largest provider of Medicare Advantage plans in 2025, behind UnitedHealth Group and Humana.

The Cigna Group (NYSE:CI) reported a strong start to 2026 and raised its full-year adjusted earnings outlook following first-quarter results that management said exceeded expectations in key areas, while also announcing additional portfolio changes and providing an update on its leadership transitio

Moby summary of Cigna Corporation's Q1 2026 earnings call

CI beats Q1 EPS estimates as Evernorth revenues jump 9% despite rising pharmacy costs; 2026 EPS outlook lifted to at least $30.35.

The move follows Aetna’s departure from the ACA market, which has seen significantly declining membership amid rising premium bills.